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cell death through apoptosis. However, this cellular demise in glaucoma is detected late by structural or functional analyses. There
can be a 10-year delay prior to the appearance of visual field defects and pre-perimetric glaucoma is an issue still being addressed.
However, a new cutting-edge technology called detection of apoptosing retinal cells (DARC) is being developed. This technique is
capable of non-invasive, real-time visualization of apoptotic changes at the cellular level. It can detect glaucomatous cell damage
at a very early stage, at the moment apoptosis starts, and thus management can be initiated even prior to development of visual
field changes. In future, this technique will also be able to provide conclusive evidence of the effectiveness of treatment protocol
and the need for any modifications which may be required. This article aims to provide a concise review of DARC technology.
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Glaucoma is a neuro-degenerative disorder characterized
by wide-spread loss of retinal ganglion cells (RGC). This RGC
demise occurs through apoptosis which is a cascade of cellu-
lar events leading to programmed cell death. Apoptosis of
RGCs is an early and critical event in the evolution of glauco-
matous visual field loss. However, it is well known that up to
20–40% of the RGCs might already be lost before the visual
field defects become apparent. This leads to an unfortunate
10-year delay in the diagnosis of glaucoma.1–3
Recently, a promising new technology has been reported
to detect RGC apoptosis in vivo. This technique is known as
‘‘Detection of Apoptosing Retinal Cells’’ (DARC). With the
application of this method it will be possible to identify
patients prior to the onset of irreversible vision loss. Apart
from diagnosis of glaucoma suspects, it will also provide a
rapid and objective assessment of the effectiveness of clinical
intervention in the patient and shorten the period of clinical
trials.1,4
This review throws light on DARC technology and its utility
in glaucoma management.Apoptosis
RGC loss in glaucoma is an important early step. RGC
demise is initiated due to a pathological event, such as ische-
mia, axonal injury or changes in the lamina cribrosa activating
apoptosis. This is a type of programmed cell death character-
ized by a carefully coordinated collapse of cellular architec-
ture associated with protein degradation and de-oxy
ribonucleic acid (DNA) fragmentation. This process is seen
in a large variety of tissues during the life cycle of the individ-
ual. It includes a genetically programmed destruction of
specific cell lines during embryogenesis, hormone-
dependent physiologic involution (such as the endometrium
during the menstrual cycle), cell death of populations (like
the intestinal epithelium and neutrophils), as well as following
cellular injury due to non-specific factors such as drugs, can-
cer and infection.5
Apoptosis differs from necrosis which causes a potentially
damaging inflammatory response. In necrosis the cell is a
passive victim and follows an energy independent mode of
death. Unlike apoptosis that can affect single-cells, necrosis
usually involves large fields of cells. Apoptosis is a neate:
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shrinkage and chromatin condensation. This is followed by
fragmentation of DNA, presumably by the activation of
endonucleases. The cells shrink, form cytoplasmic buds and
fragment into apoptotic bodies composed of membrane
bound vesicles of cytosol and organelles. This is called mem-
brane blebbing. Finally, the apoptotic bodies are extruded
from the cell and phagocytosed or degraded by macro-
phages or neighboring cells.1,3,6,7
Apoptosis consists of 2 phases:
(i) Initiation Phase: During this period a group of enzymes
called caspases become catalytically active.
(ii) Execution Phase: This is characterized by activity of
another set of caspases leading to cell death. Caspases
are a family of proteases which have a cysteine at their
active site and cleave their target proteins at specific
aspartic acids (Cysteine requiring ASPartate proteASE
activity). Caspases exist as inactive precursors or pro-
caspases known as ‘‘initiator caspases’’. Once acti-
vated, the caspases go on cleaving and activating
other caspases resulting in an amplifying proteolytic
cascade.8
Some of the activated caspases (‘‘Effector caspases’’) then
cleave a number of key proteins in the cell, including cystolic
proteins and nuclear lamins, leading to a controlled death of
the cell. Procaspases can also be triggered by activation of
‘‘death receptors’’ on the cell surface. The adaptor proteins
bind to the intracellular region of aggregated proteins caus-
ing further aggregation and subsequent cleavage of cas-
pases. This initiates the caspase cascade.8,9
An early and critical event during apoptosis is the
acquisition of surface changes by the dying cells. Other
changes also take place, including expression of throm-
bospondin binding sites, loss of sialic acid residues and
exposure of the membrane phospholipid, including
phosphotidylserine.10
In viable cells, phosphotidylserine is located in the inner
leaflet of the plasma membrane. Phospholipid binding
cytoskeletal proteins such as spectrin and aminophospholipid
translocases are assumed to play a role for this asymmetric
distribution of phosphotidylserine. During apoptosis, the
equilibrium changes with an increasing appearance of phos-
photidylserine on the outer leaflet of the plasma membrane.
This activity is probably facilitated by unknown specific intrin-
sic membrane proteins. There is evidence for the transport
(flip-flop) of phosphotidylserine from the internal to the
external leaflet of the plasma membrane as a rapidly active
process facilitated by an ATP-dependent membrane
translocase-P.10,11
Phosphotidylserine exposure precedes the nuclear
changes which define apoptosis and also precedes the loss
of plasma membrane integrity by several hours. Apparently,
five separate membrane changes occur, which lead to recog-
nition of apoptotic cells by phagocytes. The scavenging cells
recognize the apoptotic cells due to the surface phospho-
tidylserine and other receptors, finally engulfing them. This
is done without any inflammatory reaction.11
The DARC technique utilizes these activities going on in
cells, specially the early exposure of phosphotidylserine to
the outer leaflet of plasma membrane, in order to detect
RGCs in the stage of apoptosis.Please cite this article in press as: Ahmad S.S. An introduction to DARC technologDARC technique
Annexin V is a Ca++ dependent phospholipid-binding pro-
tein. It has high affinity for phosphotidylserine localized on
the outer leaflet of cell membranes. Thus, Annexin V bound
to phosphotidylserine has been utilized as a sensitive probe
for the identification of apoptosing cells.12
DARC technology has been tested on a number of animal
models. In the Morrison rat model the intra-ocular pressure is
elevated by injecting hypertonic saline into the episcleral
veins. Dark Agouti rats have also been used as apoptosis
models either by transecting the optic nerve 2–3 mm behind
the eyeball (but sparing the vasculature) or by intravitreal
injection of different doses of staurosporine. A similar stau-
rosporine primate model has been developed in macaque
monkeys. Annexin V is labeled with a fluorescent marker
(such as fluorescein isothiocyante [FITC]). This Annexin
V-FITC complex is then used as an intravitreal probe. The
ideal dose of the fluoprobe is 2.5 lg in 5 ml of PBS for the
rat and 25 lg in 5 ml of PBS for the primate model.4,5,13
An argon laser of 488 nm wavelength is scanned across the
retina to excite the fluoprobe. The emitted fluorescent rays
are focused by a confocal aperture and pass through a pair of
scanning mirrors. The fluorescence is detected by a solid-
state photodetector, having a wide band-pass filter. A confocal
scanning laser ophthalmoscope (cLSO) with image browser
software is used to assess the retina. The software is able to
compensate for any ocular movement and also improves the
signal-to-noise ratio. The fluorescent white spots, representing
apoptotic cells, are detected by a frame grabber and stored
digitally (Fig. 1). The fluoprobe bound RGCs are then counted
by manual, semi-automated or automated techniques.13–16
Manual labeling of the DARC spots can be done by the
ImageJ ‘multi-point selections’ tool. Manual counting is
regarded as the gold standard but it requires experience, is
time-consuming, monotonous, non-reproducible and subject
to observer bias.17,18
A semi-automated system has been developed by Cor-
deiro et al. In this procedure, the total number of apoptosing
RGCs for each time point in vivo is calculated and an average
density count per mm2 is generated. This DARC count is then
utilized to assess disease activity in each eye, as well as the
progression and response to treatment.14–16
Another automated cell labeling technique uses a Matlab
script. The ‘‘cells’’ are labeled in green and ‘‘non-cellular’’
structures labeled in red. The script is designed to automat-
ically count the total number of spots identified as cells.17
Annexin V binding is often done in conjunction with a vital
dye such as propidium iodide (Fig. 2). Viable cells with an
intact plasma membrane exclude propidium iodide. How-
ever, in dead or damaged cells, the plasma membrane is
leaky, allowing propidium iodide to leak inside. Thus, cells
can be tracked over time. They can progress from Annexin
V and propidium iodide negative (viable cells), to Annexin
V positive/propidium iodide negative (early apoptosis) and
finally, Annexin V and propidium iodide positive (end stage
apoptosis and death).19Advantages of DARC
There are other methods available for detection of apop-
totic cells. These include loss of cell viability (failure to eithery. Saudi J Ophthalmol (2016), http://dx.doi.org/10.1016/j.sjopt.2016.08.001
Figure 1. DARC image: Each white spot is an individual retinal ganglion cell labeled with fluorescent Annexin V undergoing apoptosis. (Published with
permission from: Cordeiro MF, Guo L, Coxon KM, Duggan J, Nizari S, Normando E, et al. Real time imaging of retinal ganglion cell apoptosis. European
Ophthalmic Review. 2010; 4: 88–91.)
Figure 2. A: Healthy cell with phosphotidylserine on the inner leaflet of plasma membrane. B: Early apoptosing cell with externalization of
phosphotidylserine. C: Binding of the fluoprobe to the exposed phosphotidylserine. D: Late apoptotic/necrotizing Propidium Iodide positive cell.
DARC technology 3exclude vital dyes or transform tetrazolium salts to colored
products), DNA fragmentation (assayed by agarose gel elec-
trophoresis or in situ terminal transferase labeling) and DNA
condensation (detected by Hoechst dye staining of nuclear
DNA). The methods providing quantitative data lack speci-
ficity, are time-consuming and usually require the destruction
of cell integrity. These assays are also based on morpholog-
ical changes and degradation of chromatin which occur late
in apoptosis.5
Annexin V binding is non-enzymatic, does not require fix-
ation and allows one to score apoptotic cells in living unfixed
samples. A clear optical media permit direct visualization of
disease processes as they occur; thus, images can be
acquired repeatedly in a non-invasive manner. DNA fragmen-
tation assays, mentioned above, are time consuming and
take 3–4 h, while Annexin V binding requires only a few
minutes.5,17
Annexin V binding enables non-invasive real time visualiza-
tion of single retinal cells undergoing apoptosis. It is alsoPlease cite this article in press as: Ahmad S.S. An introduction to DARC technologpossible to monitor changes as they occur and longitudinally
as they progress. The Annexin V assay also permits kinetic
measurements of the number of apoptotic cells in relation
to time after insult.2,14,15 In a study performed by Zhang
et al., using a 32D cell line, the Annexin V positive apoptotic
cells were scored over a period of time. A timeline of apop-
totic spots showed the following relationship: 6.6% positive
cells (At zero hours after initiation of apoptosis), 11% (at
6 h), 22% (at 8 h), 34% (at 15 h) and 40% (at 24 h).5
DARC has the potential to help elucidate the cellular
mechanisms involved in the development of RGC degenera-
tion and vision loss in glaucoma. It will also enable us to
gauge when to start treatment to prevent visual field loss
and monitor treatment effectiveness. It would provide a rapid
and objective assessment of potential and effective thera-
pies, providing a new and meaningful clinical endpoint in
glaucomatous disease. DARC has shown to provide a test
of efficacy for neuroprotective treatments in several models
of glaucoma. This test may also serve as a biomarkery. Saudi J Ophthalmol (2016), http://dx.doi.org/10.1016/j.sjopt.2016.08.001
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the duration of glaucoma clinical trials. These studies pre-
sently are dependent upon visual field status as a key end-
point and determinant of the outcome.1,2,4,11,13
Disadvantages of DARC
DARC is a fairly new and experimental technology. Thus,
the parameters and procedures for this method have not
yet been established. The intravitreal injection of fluoprobes
should be replaced with oral or perhaps intravenous routes
and operating on an office-based device to perform these
tests in order to incorporate it in the total management of
glaucoma patients. In situations where the DARC spots are
small and of low luminance, it is difficult to differentiate
between cellular and non-cellular structures (e.g. parts of
blood vessels). It is not clear how or whether apoptotic
non-RGCs may affect the DARC count. It is also not known
whether DARC would be able to differentiate between cell
deaths due to glaucoma from other causes (e.g. aging). Auto-
matic cell counting is also affected by the problem of back-
ground noise being mislabeled as cells and the large
variability in cell size limits the accuracy in identifying the
cells.1,16
Future
DARC technology can be further improved by the applica-
tion of wide-angle lenses, selection of the best wavelength in
order to enhance signal to noise ratios and improving the
correlation between in vivo and histological counts. Better
flow cytometry (FCM) techniques may allow dissemination
between different cell subpopulations, which may or may
not be involved in the apoptotic process.1,10 These additional
inputs can be incorporated into DARC studies.
Conclusion
DARC is a revolutionary new technology which is enabling
us to perform in vivo resolution and real-time and non-
invasive imaging of single cells undergoing apoptosis. This
can provide us information rapidly and over a variable period
of time. Thus, it will help us in diagnosis of RGC loss even
before visual field defects develop. This technology will also
permit an objective assessment of the efficacy of treatment
and the need to modify management of glaucoma. It remains
to be seen how this technology will be utilized in the clinical
diagnosis of glaucoma in the future.
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